Dark

Check out our Dark Pool Levels

VECT
VectivBio Holding AG
stock NASDAQ

Inactive

Jul 7, 2023

16.85USD0.000%(0.00)130,404

Pre-market

Dec 31, 1969 7:00:00 PM EST

0.00USD0.000%(0.00)0

After-hours

Dec 31, 1969 7:00:00 PM EST

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Nov 10, 2021

08:30AM EST -Pivotal STARS Program of Apraglutide in SBS-IF Progressing with Majority of Sites Activated and Screening; STARS Nutrition Interim Results Expected 1H 2022- GlobeNewswire Inc

Nov 4, 2021

07:15AM EDT VectivBio to Present at the Credit Suisse 30th Annual Healthcare GlobeNewswire Inc

Oct 20, 2021

07:16AM EDT VectivBio Announces FDA Has Cleared Co.'s IND For Apraglutide Benzinga

07:15AM EDT -FDA clears IND Application for Apraglutide for Acute Graft-Versus-Host Disease GlobeNewswire Inc

Oct 6, 2021

07:33AM EDT The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal Benzinga

Oct 5, 2021

08:01AM EDT The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout Benzinga

Sep 21, 2021

07:15AM EDT VectivBio Announces Closing of Comet Therapeutics Acquisition GlobeNewswire Inc

Sep 16, 2021

07:16AM EDT VectivBio Announces R&D Day Sept. 21 From 10:00 a.m. 12:00 p.m. EDT Benzinga

07:15AM EDT VectivBio Holding AG (VectivBio) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announcedupcoming investor events. GlobeNewswire Inc

Sep 8, 2021

07:15AM EDT VectivBio Appoints Scott Applebaum as Chief Legal Officer & GlobeNewswire Inc

Sep 3, 2021

07:15AM EDT VectivBio Holding AG (VectivBio) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, announced today that Paul R. Carter and Dr. Murray W. Stewart were elected as new members of the Board of Directors at the Extraordinary General Meeting held on September 2, 2021. GlobeNewswire Inc

Aug 31, 2021

08:15AM EDT The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical Benzinga

07:13AM EDT VectivBio To Acquire Comet Therapeutics; Terms Not Disclosed Benzinga

07:00AM EDT - Acquisition of Innovative Small Molecule Platform Significantly Expands Rare Disease Pipeline -- VectivBio to Host R&D Day on September 21, 2021- GlobeNewswire Inc

Aug 25, 2021

07:30AM EDT The Daily Biotech Pulse: Lilly Strikes $1.6B R&D Collaboration, FSD Pulls Plug On COVID-19 Program, Cassava Sinks On Questions About Alzheimer's Drug Benzinga

Aug 18, 2021

07:38AM EDT The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline Benzinga

Aug 17, 2021

08:28AM EDT The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business Benzinga

Aug 13, 2021

07:43AM EDT The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO Benzinga

Aug 12, 2021

07:15AM EDT VectivBio Publishes Invitation to the Extraordinary General Meeting GlobeNewswire Inc

Aug 6, 2021

07:42AM EDT The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO Benzinga

Aug 3, 2021

07:55AM EDT The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business Benzinga

Jul 28, 2021

07:33AM EDT The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal Benzinga

Jul 27, 2021

11:13AM EDT The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts Benzinga

Jul 22, 2021

11:34AM EDT The Daily Biotech Pulse: FDA Nod For Merck-Eisai, Seres' Ulcerative Colitis Drug Flunks Midstage Study, Pfizer To Invest In Arvinas, Absci IPO Benzinga

Jul 20, 2021

08:20AM EDT The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street Benzinga

Jul 12, 2021

07:15AM EDT - Industry veterans bring decades of clinical, regulatory and commercial management expertise to VectivBio - - Nominees will stand for election at an Extraordinary General Meeting of shareholders on September 2, 2021 - GlobeNewswire Inc

Jul 8, 2021

07:45AM EDT The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test Benzinga

Jul 7, 2021

07:41AM EDT The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend Benzinga

Jul 1, 2021

08:07AM EDT The Daily Biotech Pulse: Spero Spikes On Pfizer Investment, FDA Nod For Jazz, Orchard Signs Licensing Deal, Acumen Pharma Debuts Benzinga

Jun 30, 2021

07:29AM EDT The Daily Biotech Pulse: COVID Disappointments For Altimmune And Angion, Brickell Jumps On Hyperhidrosis Study Updates, 2 IPOs Benzinga

Jun 25, 2021

07:32AM EDT The Daily Biotech Pulse: Roche Gets Authorization For COVID-19 Treatment, Nods For Sanofi-Regeneron In Europe, Osmotica Divestment, 2 IPOs Benzinga

Jun 24, 2021

07:21AM EDT VectivBio Receives FDA Orphan Drug Designation for Apraglutide for Acute Graft-Versus-Host Disease Benzinga

07:19AM EDT VectivBio Receives FDA Orphan Drug Designation for Apraglutide for GlobeNewswire Inc

Jun 15, 2021

07:16AM EDT VectivBio Announces First Patient Dosed in Metabolic Balance Study of Apraglutide in Colon-in-Continuity Patients with Short Bowel Syndrome with Intestinal Failure Benzinga

07:15AM EDT Phase 2 trial will evaluate the efficacy of once-weekly apraglutide in increasing intestinal energy absorption in CIC patients with SBS-IFCIC patients represent over half of the total SBS-IF populationInitial readout of 4-week intestinal energy absorption data expected in 1H22 GlobeNewswire Inc

May 25, 2021

07:15AM EDT Christian Meyer, currently Chief Development Officer, to assume the newly created position of Chief Operating Officer GlobeNewswire Inc

May 14, 2021

07:59AM EDT The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts Benzinga

May 13, 2021

08:10AM EDT The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use Benzinga

May 12, 2021

08:57AM EDT The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron Benzinga

May 7, 2021

07:40AM EDT The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs Benzinga

May 6, 2021

07:49AM EDT The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom Benzinga

May 4, 2021

10:09AM EDT Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2021 Benzinga

07:19AM EDT Credit Suisse Initiates Coverage On VectivBio Holding with Outperform Rating, Announces Price Target of $24 Benzinga

07:17AM EDT B of A Securities Initiates Coverage On VectivBio Holding with Buy Rating, Announces Price Target of $19 Benzinga

07:14AM EDT SVB Leerink Initiates Coverage On VectivBio Holding with Outperform Rating, Announces Price Target of $28 Benzinga

Apr 22, 2021

08:09AM EDT The Daily Biotech Pulse: KemPharm Receives $10M Milestone Payment, Zymergen, Neuropace Debut On Nasdaq, Renalytix Wins US Government Contract, 2 IPOs Benzinga

Apr 21, 2021

07:31AM EDT The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue Benzinga

Apr 20, 2021

08:07AM EDT The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex Benzinga

Apr 14, 2021

07:51AM EDT The Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For Gilead Benzinga

Apr 13, 2021

09:53PM EDT In a press release issued under the same headline earlier today by VectivBio Holding AG(Nasdaq: VECT), please note that in the first sentence of the first paragraph, the figure of the additional ordinary shares should be 1,125,000, not 1,250,000. The corrected release follows: GlobeNewswire Inc

08:06PM EDT VectivBio Announces Closing of $146.6 Million Initial Public Offering GlobeNewswire Inc

08:16AM EDT The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug Benzinga

Apr 12, 2021

10:16AM EDT Mid-Morning Market Update: Markets Open Lower; Microsoft To Acquire Nuance Benzinga

Apr 9, 2021

11:58AM EDT VectivBio Holding Shares Open For Trade At $22.82; IPO Priced At $17/Share Benzinga

08:52AM EDT VectivBio Holding Shares Will Open For Quote At 11 a.m. EDT, Expected To Open For Trade After 11:10 a.m. EDT; IPO Priced At $17/Share Benzinga

08:51AM EDT VectivBio Late Thursday Announced Pricing Of 7.5M Share Offering At $17/Share Benzinga

Apr 8, 2021

10:27PM EDT VectivBio Announces Pricing of Initial Public Offering GlobeNewswire Inc

Share